<DOC>
	<DOC>NCT01230970</DOC>
	<brief_summary>This trial will assess the intratumoural pharmacological activity of BN83495 by changes in intratumoural levels of sex hormones and associated inhibition of steroid sulphatase (STS) activity.</brief_summary>
	<brief_title>Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female subjects 55 to 80 years with histologically or cytologically documented primary intraductal or lobular invasive breast cancer that meets the following criteria: T2, N0 or N1, M0. Primary tumour clinically determined to be 2 to 5 cm in the greatest dimension. Laboratory documentation of positive oestrogen receptor (ER+) status in at least 10% of the tumour cells. Laboratory documentation of HER2 negative status. Postmenopausal defined as no spontaneous menses for a total of 2 years amenorrheic for at least 12 months with serum oestrogen level &lt;30 pg/mL, and both luteinising hormone (LH)/follicle stimulating hormone (FSH) &gt;20 IU/L, chemotherapyinduced amenorrhoea for at least 12 months bilateral oophorectomy, or radiation castration and amenorrhoeic for at least 3 months. Eastern Cooperative Oncology Group (ECOG) performance status â‰¤2. Has locally advanced breast cancer that is considered nonoperable without neoadjuvant therapy. Has evidence of metastatic disease as a diagnosis of inflammatory breast cancer Has ductal carcinoma in situ</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>